FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2590996984> ?p ?o ?g. }

• W2590996984 endingPage "631" @default.
• W2590996984 startingPage "631" @default.
• W2590996984 abstract "631 Background: Third-generation nonsteroidal aromatase inhibitors (AIs) are used as adjuvant and 1st-line metastatic therapy for postm HR+ ABC. However, many patients (pts) subsequently experience disease progression. A phase 2 study of the Src/Abl kinase inhibitor bosutinib (BOS) as monotherapy (400 mg) in unselected, heavily pretreated ABC pts revealed an overall response rate (ORR) of 9.4% and 16-wk progression-free survival (PFS) rate of 29.8%, with a median PFS of 9.9 wks. As all responses were seen in HR+ pts, combination BOS and endocrine therapy was explored. Methods: This randomized, open-label, multicenter, phase 2 trial evaluated BOS and EXE vs EXE alone as 2nd-line therapy after AI failure in postm HR+ HER2– ABC. The primary end point was PFS. Prior to randomization, a 28-day safety lead-in phase was conducted; BOS 400 mg/EXE 25 mg was administered orally once daily, with reduction to BOS 300 mg if the higher dose had unacceptable toxicity. Results: 42 pts participated in the safety lead-in phase. 14 pts received BOS 400 mg/EXE 25 mg; common drug-related adverse events (AEs; any grade/grade ≥3) were diarrhea (93%/7%), nausea (79%/7%), vomiting (57%/0), increased alanine aminotransferase (ALT; 29%/29%), increased aspartate aminotransferase (AST; 21%/0), fatigue, (21%/0), and rash (21%/0). 5 of 13 (38.5%) evaluable pts experienced a dose-limiting toxicity (DLT) of increased ALT (n = 4), increased AST (n = 1), diarrhea (n = 1), and vomiting (n = 1). Therefore, another 28 pts were enrolled at a dose of BOS 300 mg/EXE 25 mg. At this dose level, grade ≥3 drug-related AEs included diarrhea (11%), nausea (7%), and ALT elevations (4%). Across dose levels, 5 pts discontinued due to diarrhea. All transaminase elevations were reversible upon BOS discontinuation. Median investigator-assessed PFS was 12.3 wks, and the ORR was 3.6%. Conclusions: The safety profile of BOS 300 mg/EXE 25 mg was generally manageable, albeit with limited efficacy. Because of the lower than expected efficacy and high rate of transaminase elevations, this study was stopped prematurely. Given prior evidence of efficacy of BOS monotherapy, new regimens with BOS should be explored for ABC." @default.
• W2590996984 created "2017-03-03" @default.
• W2590996984 creator A5005182505 @default.
• W2590996984 creator A5007579054 @default.
• W2590996984 creator A5008379155 @default.
• W2590996984 creator A5025238669 @default.
• W2590996984 creator A5025530232 @default.
• W2590996984 creator A5053795537 @default.
• W2590996984 creator A5056604670 @default.
• W2590996984 creator A5057481247 @default.
• W2590996984 creator A5059044277 @default.
• W2590996984 creator A5062030620 @default.
• W2590996984 creator A5066504786 @default.
• W2590996984 creator A5081396969 @default.
• W2590996984 date "2011-05-20" @default.
• W2590996984 modified "2023-09-26" @default.
• W2590996984 title "Bosutinib and exemestane (EXE) versus EXE alone in postmenopausal (postm) women with hormone receptor–positive (HR+) HER2-negative (HER2–) advanced breast cancer (ABC)." @default.
• W2590996984 doi "https://doi.org/10.1200/jco.2011.29.15_suppl.631" @default.
• W2590996984 hasPublicationYear "2011" @default.
• W2590996984 type Work @default.
• W2590996984 sameAs 2590996984 @default.
• W2590996984 citedByCount "1" @default.
• W2590996984 countsByYear W25909969842013 @default.
• W2590996984 crossrefType "journal-article" @default.
• W2590996984 hasAuthorship W2590996984A5005182505 @default.
• W2590996984 hasAuthorship W2590996984A5007579054 @default.
• W2590996984 hasAuthorship W2590996984A5008379155 @default.
• W2590996984 hasAuthorship W2590996984A5025238669 @default.
• W2590996984 hasAuthorship W2590996984A5025530232 @default.
• W2590996984 hasAuthorship W2590996984A5053795537 @default.
• W2590996984 hasAuthorship W2590996984A5056604670 @default.
• W2590996984 hasAuthorship W2590996984A5057481247 @default.
• W2590996984 hasAuthorship W2590996984A5059044277 @default.
• W2590996984 hasAuthorship W2590996984A5062030620 @default.
• W2590996984 hasAuthorship W2590996984A5066504786 @default.
• W2590996984 hasAuthorship W2590996984A5081396969 @default.
• W2590996984 hasConcept C126322002 @default.
• W2590996984 hasConcept C197934379 @default.
• W2590996984 hasConcept C2778496288 @default.
• W2590996984 hasConcept C2778570526 @default.
• W2590996984 hasConcept C2780580376 @default.
• W2590996984 hasConcept C29730261 @default.
• W2590996984 hasConcept C71924100 @default.
• W2590996984 hasConcept C90924648 @default.
• W2590996984 hasConceptScore W2590996984C126322002 @default.
• W2590996984 hasConceptScore W2590996984C197934379 @default.
• W2590996984 hasConceptScore W2590996984C2778496288 @default.
• W2590996984 hasConceptScore W2590996984C2778570526 @default.
• W2590996984 hasConceptScore W2590996984C2780580376 @default.
• W2590996984 hasConceptScore W2590996984C29730261 @default.
• W2590996984 hasConceptScore W2590996984C71924100 @default.
• W2590996984 hasConceptScore W2590996984C90924648 @default.
• W2590996984 hasIssue "15_suppl" @default.
• W2590996984 hasLocation W25909969841 @default.
• W2590996984 hasOpenAccess W2590996984 @default.
• W2590996984 hasPrimaryLocation W25909969841 @default.
• W2590996984 hasRelatedWork W1541193958 @default.
• W2590996984 hasRelatedWork W1980701009 @default.
• W2590996984 hasRelatedWork W2243375749 @default.
• W2590996984 hasRelatedWork W2350328551 @default.
• W2590996984 hasRelatedWork W2378568667 @default.
• W2590996984 hasRelatedWork W2415671716 @default.
• W2590996984 hasRelatedWork W2468742732 @default.
• W2590996984 hasRelatedWork W2480155873 @default.
• W2590996984 hasRelatedWork W4235272272 @default.
• W2590996984 hasRelatedWork W4313236518 @default.
• W2590996984 hasVolume "29" @default.
• W2590996984 isParatext "false" @default.
• W2590996984 isRetracted "false" @default.
• W2590996984 magId "2590996984" @default.
• W2590996984 workType "article" @default.